Drugs for Medical Management of Obesity

• Titel: Drugs for Medical Management of Obesity
• Titelzusatz: A Machine-Generated Literature Overview
• Mitwirkende: Garcha, Shilpa Chugh [HerausgeberIn]
• Mitwirkende: Kalra, Sanjay [HerausgeberIn]
• Verf.angabe: edited by Shilpa Chugh Garcha, Sanjay Kalra
• Ausgabe: 1st ed. 2025.
• Verlagsort: Singapore
• Verlagsort: Singapore
• Verlag: Springer Nature Singapore
• Verlag: Imprint: Springer
• E-Jahr: 2025
• Jahr: 2025.
• Jahr: 2025.
• Umfang: 1 Online-Ressource(XI, 182 p.)
• ISBN: 978-981-9616-51-0
• DOI: doi:10.1007/978-981-96-1651-0
• Datenträger: Online-Ressource
• Sprache: eng
• Bibliogr. Hinweis: Erscheint auch als : Druck-Ausgabe
• Bibliogr. Hinweis: Erscheint auch als : Druck-Ausgabe
• Bibliogr. Hinweis: Erscheint auch als : Druck-Ausgabe
• K10plus-PPN: 1920027645
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext
• Lokale URL UB: Bibliothek der Medizinischen Fakultät Mannheim der Universität Heidelberg
• Bibliothek/Idn: UW / m4688002009
• Lokale URL Inst.: Zum Volltext

Abstract

Chapter 1 Introduction to obesity and Anti-Obesity Medications -- Chapter 2 Orlistat: A Gastrointestinal Lipase Inhibitor -- Chapter 3 Fixed Combination Anti-Obesity Medications -- Chapter 4 Role of Incretin Mimetics in the Management of Obesity -- Chapter 5 Anti-Obesity Medications for Monogenic Syndromic Obesity -- Chapter 6 Future Perspectives in the Management of Obesity -- Chapter 7 Person-Centered Approach and Challenges in the Management of Obesity.

Abstract

This book covers pharmacological activity and the role of the medications used for the medical management of obesity. The chapters provide information on the prevalence of obesity, basic principles of obesity management, a brief history of anti-obesity medications (AOMs), and discontinuation of AOMs due to their safety concerns. Further chapters include information on currently approved AOMs for obesity management by healthcare regulatory authorities including their effect on weight loss and other important clinical parameters, short-term and long-term use of AOMs, medications for genetic obesity, and the use of AOMs in obesity with associated co-morbidities as per their safety considerations and contraindications. A separate chapter is on drugs that are either under a clinical trial phase or awaiting approval. The auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the external editor. The editor of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that the auto-summaries consist of original sentences, but are not representative of the original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here and that machine-generated books are still at an experimental stage The book is relevant for healthcare and pharmaceutical professionals.